Literature DB >> 29357429

Sweet success? SGLT2 inhibitors and diabetes.

Anita T Layton1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29357429      PMCID: PMC6032073          DOI: 10.1152/ajprenal.00557.2017

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


× No keyword cloud information.
  18 in total

1.  Harnessing basic and clinic tools to evaluate SGLT2 inhibitor nephrotoxicity.

Authors:  Danielle L Saly; Mark A Perazella
Journal:  Am J Physiol Renal Physiol       Date:  2017-06-21

2.  Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats.

Authors:  Julie O'Neill; Angelica Fasching; Liselotte Pihl; Daniela Patinha; Stephanie Franzén; Fredrik Palm
Journal:  Am J Physiol Renal Physiol       Date:  2015-06-03

Review 3.  Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.

Authors:  Raymond V Oliva; George L Bakris
Journal:  J Am Soc Hypertens       Date:  2014-02-12

Review 4.  Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition.

Authors:  V Tsimihodimos; T D Filippatos; S Filippas-Ntekouan; M Elisaf
Journal:  Curr Vasc Pharmacol       Date:  2017       Impact factor: 2.719

5.  Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition.

Authors:  Anita T Layton; Volker Vallon; Aurélie Edwards
Journal:  Am J Physiol Renal Physiol       Date:  2015-04-08

6.  A computational model for simulating solute transport and oxygen consumption along the nephrons.

Authors:  Anita T Layton; Volker Vallon; Aurélie Edwards
Journal:  Am J Physiol Renal Physiol       Date:  2016-10-05

7.  Tubular dysfunction and hemodynamic alteration in normoalbuminuric type 2 diabetes.

Authors:  Narisa Futrakul; Varaphon Vongthavarawat; Sasitorn Sirisalipotch; Tawatchai Chairatanarat; Prasit Futrakul; Sompongse Suwanwalaikorn
Journal:  Clin Hemorheol Microcirc       Date:  2005       Impact factor: 2.375

8.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

9.  Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron.

Authors:  Anita T Layton; Volker Vallon; Aurélie Edwards
Journal:  Am J Physiol Renal Physiol       Date:  2016-01-13

10.  SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.

Authors:  Volker Vallon; Maria Gerasimova; Michael A Rose; Takahiro Masuda; Joseph Satriano; Eric Mayoux; Hermann Koepsell; Scott C Thomson; Timo Rieg
Journal:  Am J Physiol Renal Physiol       Date:  2013-11-13
View more
  2 in total

1.  Recent advances in renal epithelial transport.

Authors:  Anita T Layton
Journal:  Am J Physiol Renal Physiol       Date:  2018-12-05

Review 2.  A Computational Model of Kidney Function in a Patient with Diabetes.

Authors:  Rui Hu; Anita Layton
Journal:  Int J Mol Sci       Date:  2021-05-29       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.